Gapping up
News:
- CRNX +64.1% (Crinetics' once-daily oral Paltusotine achieved the primary and all secondary endpoints in the Phase 3 PATHFNDR-1 Study evaluating treatment of patients with acromegaly)
- BLRX +18.7% (FDA has approved APHEXDA)
- IBRX +15.5% (announces $470 million equity and debt financing from founder Dr. Patrick Soon-Shiong and Nant Entities)
- TWNK +14.9% (Hostess Brands deal to be acquired by J.M. Smucker (SJM) could be announced today according to WSJ)
- QCOM +8.6% (enters agreement with Apple (AAPL) for Snapdragon 5G Modem-RF Systems supply)
- IVVD +7.9% (Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19)
- VIGL +6.7% (Announces Update on its Small Molecule TREM2 Agonist Program)
- IMTX +4.6% (entered into a Master Collaboration and License Agreement with ModernaTX)
- GROV +3.4% (files for 6340019 shares of common stock by selling shareholder)
- FREY +3.4% (Files Form S-4 for Redomicile from Luxembourg to U.S.)
- VRNA +3.3% (receives FDA acceptance of NDA filing for Ensifentrine for the maintenance treatment of COPD)
- MBLY +1.5% (new CFO)
- PLL +1.5% (announced that the Minerals Income Investment Fund of Ghana agreed to invest $27.9 million to acquire a 6% stake in the Ewoyaa Lithium Project and an additional $5 million in Piedmont partner Atlantic Lithium Limited)
- CRMD +1.4% (CEO bought 10000 shares at $3.71 worth ~$37K)
Analyst comments:
- TSLA +6.2% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- NU +3.7% (upgraded to Overweight from Neutral at JP Morgan)
- TENB +3.1% (upgraded to Overweight from Neutral at JP Morgan)
- DASH +2.4% (upgraded to Hold from Underperform at Jefferies)
- BF.B +0.8% (upgraded to Outperform from Mkt Perform at Bernstein)